Quest Diagnostics Management

Management Kriterienprüfungen 3/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Jim Davis

Geschäftsführender

US$12.7m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	9.3%
Amtszeit als Geschäftsführer	2yrs
Eigentum des Geschäftsführers	0.07%
Durchschnittliche Amtszeit des Managements	4yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	5.2yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Jim Davis im Vergleich zu den Einnahmen von Quest Diagnostics verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Sep 30 2024	n/a	n/a	US$838m
Jun 30 2024	n/a	n/a	US$836m
Mar 31 2024	n/a	n/a	US$842m
Dec 31 2023	US$13m	US$1m	US$850m
Sep 30 2023	n/a	n/a	US$759m
Jun 30 2023	n/a	n/a	US$790m
Mar 31 2023	n/a	n/a	US$789m
Dec 31 2022	US$12m	US$806k	US$942m
Sep 30 2022	n/a	n/a	US$1b
Jun 30 2022	n/a	n/a	US$1b
Mar 31 2022	n/a	n/a	US$2b
Dec 31 2021	US$4m	US$625k	US$2b
Sep 30 2021	n/a	n/a	US$2b
Jun 30 2021	n/a	n/a	US$2b
Mar 31 2021	n/a	n/a	US$2b
Dec 31 2020	US$4m	US$577k	US$1b
Sep 30 2020	n/a	n/a	US$1b
Jun 30 2020	n/a	n/a	US$749m
Mar 31 2020	n/a	n/a	US$771m
Dec 31 2019	US$3m	US$590k	US$835m
Sep 30 2019	n/a	n/a	US$709m
Jun 30 2019	n/a	n/a	US$707m
Mar 31 2019	n/a	n/a	US$720m
Dec 31 2018	US$3m	US$590k	US$733m
Sep 30 2018	n/a	n/a	US$860m
Jun 30 2018	n/a	n/a	US$808m
Mar 31 2018	n/a	n/a	US$782m
Dec 31 2017	US$3m	US$590k	US$769m

Vergütung im Vergleich zum Markt: JimDie Gesamtvergütung ($USD12.67M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt UK ($USD5.69M).

Entschädigung vs. Einkommen: JimDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Jim Davis (61 yo)

2yrs

Amtszeit

US$12,673,834

Vergütung

Mr. James E. Davis, also known as Jim, serves as Chief Executive Officer and President at Quest Diagnostics Incorporated since November 1, 2022 and serves as its Director since November 2022. He served as...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
James Davis	Chairman	2yrs	US$12.67m	0.067% $ 12.3m
Sam Samad	Executive VP & CFO	2.3yrs	US$3.98m	0.016% $ 2.9m
Michael Prevoznik	Senior VP & General Counsel	25.3yrs	US$2.25m	0.039% $ 7.2m
Catherine Doherty	Executive Vice President of Regional Businesses	no data	US$3.16m	0.058% $ 10.6m
Karthik Kuppusamy	Senior Vice President of Clinical Solutions	2.3yrs	US$2.02m	0.010% $ 1.9m
Michael Deppe	Senior VP	5.6yrs	keine Daten	0.032% $ 5.8m
Murali Balakumar	Senior VP	less than a year	keine Daten	keine Daten
Shawn Bevec	Vice President of Investor Relations	no data	keine Daten	keine Daten
Kristin Wallace	Senior VP & Chief Compliance Officer	2.1yrs	keine Daten	keine Daten
Gary Samuels	Senior VP & Chief Communications Officer	28yrs	keine Daten	keine Daten
Cecilia McKenney	Senior VP & Chief Human Resources Officer	6.8yrs	keine Daten	keine Daten
Dermot Shorten	Senior Vice President of Strategy	8.8yrs	keine Daten	keine Daten

4.0yrs

Durchschnittliche Betriebszugehörigkeit

61yo

Durchschnittliches Alter

Erfahrenes Management: 0KSXDas Führungsteam des Unternehmens gilt als erfahren (4 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
James Davis	Chairman	2yrs	US$12.67m	0.067% $ 12.3m
Timothy Main	Independent Director	10.8yrs	US$315.44k	0.022% $ 4.1m
Robert Carter	Director	less than a year	keine Daten	keine Daten
Timothy Ring	Lead Independent Director	12.9yrs	US$345.94k	keine Daten
Gary Pfeiffer	Independent Director	19.9yrs	US$342.12k	keine Daten
Denise Morrison	Independent Director	5.8yrs	US$312.33k	0.0026% $ 470.1k
Vicky Gregg	Independent Director	10.3yrs	US$315.73k	0.016% $ 3.0m
Wright Lassiter	Independent Director	4.7yrs	US$300.44k	keine Daten
Tracey Doi	Independent Director	3.3yrs	US$300.44k	keine Daten
Luiz Diaz	Independent Director	1.5yrs	US$280.41k	keine Daten

5.2yrs

Durchschnittliche Betriebszugehörigkeit

65yo

Durchschnittliches Alter

Erfahrener Vorstand: 0KSXDie Vorstandsmitglieder gelten als erfahren (5.2 Jahre durchschnittliche Amtszeit).

Quest Diagnostics Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Quest Diagnostics Elects Robert B. Carte to Board of Directors

Quest Diagnostics Appoints Murali Balakumar as Senior Vice President and Chief Information and Digital Officer

Quest Diagnostics Incorporated, Annual General Meeting, May 16, 2024

Quest Diagnostics, Inc. Appoints Yuri A. Fesko, M.D. as Senior Vice President and Chief Medical Officer

Quest Diagnostics Elects Luis A. Diaz to Its Board

Quest Diagnostics Announces Jim Davis Joins Board of Directors

Recent updates

Third quarter dividend of US$0.75 announced

Quest Diagnostics Declares Quarterly Cash Dividend, Payable on January 29, 2025

Quest Diagnostics Incorporated Updates Earnings Outlook for 2024

Third quarter 2024 earnings released: EPS: US$2.02 (vs US$1.99 in 3Q 2023)

Quest Diagnostics Incorporated Updates Earnings Outlook for 2024

Quest Diagnostics Introduces Specimen Self-Collection for Common Genital Tract Infection Testing at Nationwide Network of Patient Service Centers

Quest Diagnostics Incorporated (NYSE:DGX) completed the acquisition of Select Assets of Outreach Laboratory Services Business of University Hospitals from University Hospitals Health System, Inc.

Upcoming dividend of US$0.75 per share

Quest Diagnostics Incorporated to Report Q3, 2024 Results on Oct 22, 2024

Quest Diagnostics Incorporated (NYSE:DGX) completed the acquisition of Select laboratory assets of Allina Health System, Inc.

Second quarter dividend of US$0.75 announced

Quest Diagnostics Incorporated Introduces 13 New Blood Tests to Identify Micronutrient Deficiencies

Second quarter 2024 earnings released: EPS: US$2.05 (vs US$2.09 in 2Q 2023)

Quest Diagnostics Incorporated Updates Earnings Guidance for the Full Year of 2024

Upcoming dividend of US$0.75 per share

Quest Diagnostics Incorporated to Report Q2, 2024 Results on Jul 23, 2024

Quest Diagnostics Incorporated (NYSE:DGX) completed the acquisition of Select assets of PathAI Diagnostics.

First quarter dividend of US$0.75 announced

Quest Diagnostics Elects Robert B. Carte to Board of Directors

Quest Diagnostics Incorporated Declares Quarterly Cash Dividend, Payable on July 22, 2024

Quest Diagnostics Appoints Murali Balakumar as Senior Vice President and Chief Information and Digital Officer

First quarter 2024 earnings released: EPS: US$1.75 (vs US$1.80 in 1Q 2023)

Quest Diagnostics Incorporated Updates Earnings Guidance for the Full Year of 2024

Quest Diagnostics Incorporated, Annual General Meeting, May 16, 2024

Upcoming dividend of US$0.75 per share

Quest Diagnostics Incorporated to Report Q1, 2024 Results on Apr 23, 2024

Full year 2023 earnings released: EPS: US$7.59 (vs US$8.12 in FY 2022)

Quest Diagnostics Incorporated Announces the Launch of MelaNodal Predict

Quest Diagnostics Incorporated Announces the Availability of the First Consumer-Initiated, Physician-Ordered Blood-Draw Test for PFAS Chemicals

Dividend of US$0.75 announced

Full year 2023 earnings released: EPS: US$7.63 (vs US$8.12 in FY 2022)

Quest Diagnostics Incorporated Provides Earnings Guidance for the Full Year of 2024

Quest Diagnostics Incorporated to Report Q4, 2023 Results on Feb 01, 2024

Upcoming dividend of US$0.71 per share at 2.0% yield

Quest Diagnostics, Inc. Appoints Yuri A. Fesko, M.D. as Senior Vice President and Chief Medical Officer

Quest Diagnostics Launches New 88-Compound Novel Psychoactive Substance Test Panel

Quest Diagnostics Declares Quarterly Cash Dividend, Payable on January 31, 2024

Quest Diagnostics Launches Mobile Phlebotomy Service, Enabling Convenient At-Home Specimen Collection in the United States

Third quarter 2023 earnings released: EPS: US$1.99 (vs US$2.19 in 3Q 2022)

Quest Diagnostics Incorporated Updates Earnings Guidance for the Full Year 2023

Quest Diagnostics Incorporated to Report Q3, 2023 Results on Oct 24, 2023

Upcoming dividend of US$0.71 per share at 2.3% yield

Quest Diagnostics Grants Fda Breakthrough Designation for Its Adeno-Associated Virus Test

Quest Diagnostics Incorporated Declares Quarterly Cash Dividend, Payable on October 23, 2023

QuQuest Diagnostics Introduces First-To-Market Consumer-Initiated Blood Test for Alzheimer's Disease Risk Assessment on questhealth.com

Quest Diagnostics Incorporated Revises Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: EPS: US$2.09 (vs US$1.99 in 2Q 2022)

Quest Diagnostics Announces the Launch of its First Consumer-Initiated Genetic Test

Upcoming dividend of US$0.71 per share at 2.0% yield

Quest Diagnostics Incorporated to Report Q2, 2023 Results on Jul 26, 2023

Quest Diagnostics Elects Luis A. Diaz to Its Board

Quest Diagnostics Declares Quarterly Cash Dividend, Payable on July 25, 2023

First quarter 2023 earnings released: EPS: US$1.80 (vs US$2.98 in 1Q 2022)

Now 20% undervalued

Upcoming dividend of US$0.71 per share at 2.1% yield

Quest Diagnostics Incorporated (NYSE:DGX) entered into a definitive agreement to acquire Select Assets of the Laboratory Services Business from The New York and Presbyterian Hospital.

Now 20% undervalued after recent price drop

Full year 2022 earnings released: EPS: US$8.12 (vs US$15.90 in FY 2021)

Quest Diagnostics Incorporated Provides Earnings Guidance for the Full Year of 2023

Quest Diagnostics Incorporated to Report Q4, 2022 Results on Feb 02, 2023

Upcoming dividend of US$0.66 per share

Quest Diagnostics Incorporated (NYSE:DGX) completed the acquisition of Select assets of Summa Health System, Inc.

Quest Diagnostics Declares Quarterly Cash Dividend, Payable on February 1, 2023

Quest Diagnostics Announces Jim Davis Joins Board of Directors

Third quarter 2022 earnings released: EPS: US$2.19 (vs US$4.09 in 3Q 2021)

Quest Diagnostics Incorporated Announces Executive Changes

Quest Diagnostics Incorporated Announces Management Changes

Quest Diagnostics Incorporated (NYSE:DGX) entered into a definitive agreement to acquire Select assets of Summa Health System, Inc.

Quest Diagnostics Incorporated to Report Q3, 2022 Results on Oct 20, 2022